We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Awards Merck KGaA, Pfizer Breakthrough Therapy Designation for Avelumab

FDA Awards Merck KGaA, Pfizer Breakthrough Therapy Designation for Avelumab

pfizerlogo.gif
November 24, 2015

German drugmaker Merck KGaA and Pfizer have received breakthrough therapy designation for avelumab as a second-line treatment for metastatic Merkel cell carcinoma.

Avelumab is an anti-PD-L1 IgG1 monoclonal antibody designed for use with difficult-to-treat cancers, such as MCC, a rare and aggressive skin cancer with no approved treatment other than surgery, chemotherapy or radiation therapy.

The designation is based on preliminary data from a global Phase 2 study that showed the candidate may demonstrate a substantial improvement over current therapies. Final results will be presented next year.

The alliance between the two companies for joint development of the drug is less than two months old, yet already has produced its third FDA milestone, including orphan drug designation in September and fast track designation in October. Pfizer paid $850 million upfront for Merck KGaA’s immunotherapy pipeline last November.

The two companies also plan to investigate avelumab in other tumor types, such as head and neck cancer, mesothelioma, melanoma, non-small cell lung cancer, ovarian cancer, renal cell carcinoma and bladder cancer.

Separately, Merck KGaA announced last week that it had completed its $17 billion acquisition of St. Louis, Mo.-based Sigma-Aldrich, a chemicals and biologics company. The move will boost Merck’s supply chain and support the delivery of more than 300,000 products, the company has said.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

  • FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

  • FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

  • FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing